{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:49:11Z","timestamp":1773186551908,"version":"3.50.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.numecd.2025.104214","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:59:31Z","timestamp":1751425171000},"page":"104214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Consensus document on the role of plasma triglycerides in cardiovascular disease from the Italian Society for the Study of Atherosclerosis (SISA)"],"prefix":"10.1016","volume":"35","author":[{"given":"Alberto","family":"Zambon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4231-4150","authenticated-orcid":false,"given":"Federica","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Manzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Giaccari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Sesti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Belfiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe D.","family":"Norata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Temporelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Frulloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Poli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2025.104214_bib1","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104214_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104214_bib3","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0022-2275(20)38739-3","article-title":"Modifications of plasma lipoproteins after lipase activation in patients with chylomicronemia","volume":"27","author":"Manzato","year":"1986","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2025.104214_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tem.2020.11.005","article-title":"Lipoprotein lipase and its regulators: an unfolding story","volume":"32","author":"Wu","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.numecd.2025.104214_bib5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: from pathophysiology to pharmacology","volume":"36","author":"Norata","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.numecd.2025.104214_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41575-019-0250-7","article-title":"Regulation of intestinal lipid metabolism: current concepts and relevance to disease","volume":"17","author":"Ko","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2025.104214_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41569-022-00676-y","article-title":"Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia","volume":"19","author":"Boren","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2025.104214_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.numecd.2025.104214_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2019.12.005","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"294","author":"Nordestgaard","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2025.104214_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104214_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","article-title":"Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management","volume":"72","author":"Ganda","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib13","article-title":"Management of hypertriglyceridemia","volume":"371","author":"Simha","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2025.104214_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \"FCS score\"","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2025.104214_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","article-title":"Current knowledge of hypertriglyceridemic pancreatitis","volume":"25","author":"Valdivielso","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.numecd.2025.104214_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","article-title":"Issues in hypertriglyceridemic pancreatitis: an update","volume":"48","author":"Scherer","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.numecd.2025.104214_bib17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00004836-200301000-00016","article-title":"Issues in hyperlipidemic pancreatitis","volume":"36","author":"Yadav","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.numecd.2025.104214_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/2050640618755002","article-title":"Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management","volume":"6","author":"de Pretis","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.numecd.2025.104214_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002573","article-title":"Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity","volume":"3","author":"Navina","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.numecd.2025.104214_bib20","article-title":"Relationship between plasma triglyceride level and severity of hypertriglyceridemic pancreatitis","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2025.104214_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MOG.0000000000000386","article-title":"Obesity and pancreatitis","volume":"33","author":"Khatua","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.numecd.2025.104214_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1194\/jlr.P119000543","article-title":"LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL","volume":"61","author":"Chapman","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2025.104214_bib23","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dbi19-0007","article-title":"Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease","volume":"69","author":"Chait","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2025.104214_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1373\/clinchem.2007.093492","article-title":"Association of cystic fibrosis transmembrane conductance regulator (CFTR) mutation\/variant\/haplotype and tumor necrosis factor (TNF) promoter polymorphism in hyperlipidemic pancreatitis","volume":"54","author":"Chang","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.numecd.2025.104214_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1499-3872(11)60131-8","article-title":"Triglyceride levels and apolipoprotein E polymorphism in patients with acute pancreatitis","volume":"11","author":"Ivanova","year":"2012","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.numecd.2025.104214_bib26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archinternmed.2008.599","article-title":"Hypertriglyceridemia and its pharmacologic treatment among US adults","volume":"169","author":"Ford","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.numecd.2025.104214_bib27","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/js.2019-00129","article-title":"Very severe hypertriglyceridemia in a large US county health care system: associated conditions and management","volume":"3","author":"Esparza","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.numecd.2025.104214_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2337\/diab.31.3.217","article-title":"Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus","volume":"31","author":"Kissebah","year":"1982","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2025.104214_bib29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New insights into the pathophysiology of dyslipidemia in type 2 diabetes","volume":"239","author":"Taskinen","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2025.104214_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2015.04.810","article-title":"Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: a nationwide survey of 2674 individuals in Hungary","volume":"241","author":"Mark","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2025.104214_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.yjmcc.2006.01.022","article-title":"Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: molecular mechanisms and gene expression studies","volume":"40","author":"Norata","year":"2006","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.atherosclerosis.2009.03.017","article-title":"Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells","volume":"206","author":"Norata","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2025.104214_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2006.09.015","article-title":"Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies","volume":"193","author":"Norata","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2025.104214_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from Epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2025.104214_bib35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/01.ATV.21.2.282","article-title":"Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia","volume":"21","author":"Guerin","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2025.104214_bib36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12933-014-0159-y","article-title":"Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor","volume":"13","author":"Tenenbaum","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2025.104214_bib37","doi-asserted-by":"crossref","first-page":"474","DOI":"10.7326\/0003-4819-150-7-200904070-00007","article-title":"Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes","volume":"150","author":"Ip","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2025.104214_bib38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fendo.2020.00252","article-title":"Causes and consequences of hypertriglyceridemia","volume":"11","author":"Packard","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.numecd.2025.104214_bib39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2362.1986.tb01322.x","article-title":"Lipoprotein modifications during dietary treatment in patients with primary type V hyperlipoproteinaemia","volume":"16","author":"Manzato","year":"1986","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.numecd.2025.104214_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0009-8981(93)90197-C","article-title":"Levels and physicochemical properties of lipoprotein subclasses in moderate hypertriglyceridemia","volume":"219","author":"Manzato","year":"1993","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.numecd.2025.104214_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib42","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ahj.2014.08.007","article-title":"Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study","volume":"168","author":"Andersson","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2025.104214_bib43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2025.104214_bib44","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Emerging Risk Factors","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2025.104214_bib45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","article-title":"Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease","volume":"104","author":"Faergeman","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib46","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2008.621","article-title":"Nonfasting triglycerides and risk of ischemic stroke in the general population","volume":"300","author":"Freiberg","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2025.104214_bib47","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib48","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2025.104214_bib49","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2025.104214_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00145359","article-title":"The importance of triglycerides: results from the prospective cardiovascular munster (PROCAM) study","volume":"8","author":"Assmann","year":"1992","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.numecd.2025.104214_bib51","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2025.104214_bib52","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104214_bib53","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib54","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.numecd.2025.104214_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009501","article-title":"ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease","volume":"17","author":"Helkkula","year":"2021","journal-title":"PLoS Genet"},{"key":"10.1016\/j.numecd.2025.104214_bib57","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2017.0972","article-title":"Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease","volume":"317","author":"Khera","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2025.104214_bib58","article-title":"A promoter variant of the APOA5 gene increases atherogenic LDL levels and arterial stiffness in hypertriglyceridemic patients","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2025.104214_bib59","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2018.2866","article-title":"Association of genetically enhanced lipoprotein lipase-mediated lipolysis and low-density lipoprotein cholesterol-lowering alleles with risk of coronary disease and type 2 diabetes","volume":"3","author":"Lotta","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib60","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease","volume":"374","author":"Myocardial Infarction","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Blood","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib62","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib63","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib64","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2025.104214_bib65","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib66","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2025.104214_bib68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2025.104214_bib69","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/bmj.325.7373.1139","article-title":"Bezafibrate in men with lower extremity arterial disease: randomised controlled trial","volume":"325","author":"Meade","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2025.104214_bib70","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2025.104214_bib71","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib72","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib73","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400179","article-title":"Effect of fenofibrate on progression of diabetic retinopathy","volume":"3","author":"Preiss","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.numecd.2025.104214_bib74","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","article-title":"Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia","volume":"16","author":"Fruchart","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2025.104214_bib75","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib76","doi-asserted-by":"crossref","first-page":"44","DOI":"10.56095\/eaj.v2i3.55","article-title":"Is there still a place for fenofibrate-statin combination therapy? Fenofibrate-statin combination therapy","volume":"2","author":"Farnier","year":"2023","journal-title":"Euro Atherosclerosis J"},{"key":"10.1016\/j.numecd.2025.104214_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib78","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.amjmed.2021.03.014","article-title":"Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction","volume":"134","author":"Mason","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib79","doi-asserted-by":"crossref","first-page":"J34","DOI":"10.1093\/eurheartj\/suaa117","article-title":"Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies","volume":"22","author":"Olshansky","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.numecd.2025.104214_bib80","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2025.104214_bib81","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2025.104214_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106873","article-title":"Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment","volume":"195","author":"Galimberti","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.numecd.2025.104214_bib83","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","article-title":"Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM","volume":"64","author":"Langlois","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.numecd.2025.104214_bib84","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/CIRCULATIONAHA.117.030677","article-title":"Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy","volume":"137","author":"Sathiyakumar","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2025.104214_bib85","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2025.104214_bib86","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5551\/jat.42440","article-title":"The effects of long-term dietary therapy on patients with hypertriglyceridemia","volume":"26","author":"Yamanaka","year":"2019","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.numecd.2025.104214_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/nu8080455","article-title":"Dietary interventions and changes in cardio-metabolic parameters in metabolically healthy obese subjects: a systematic review with meta-analysis","volume":"8","author":"Stelmach-Mardas","year":"2016","journal-title":"Nutrients"},{"key":"10.1016\/j.numecd.2025.104214_bib88","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ajcn\/77.5.1146","article-title":"Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials","volume":"77","author":"Mensink","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.numecd.2025.104214_bib89","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jacc.2020.11.060","article-title":"Cardiovascular impact of nutritional supplementation with omega-3 fatty acids: JACC focus seminar","volume":"77","author":"Weinberg","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib90","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001700","article-title":"Effect of fructose on established lipid targets: a systematic review and meta-analysis of controlled feeding trials","volume":"4","author":"Chiavaroli","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2025.104214_bib91","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/lipd.12237","article-title":"Dietary alcohol and fat differentially affect plasma cholesteryl ester transfer activity and triglycerides in normo- and hypertriglyceridemic subjects","volume":"55","author":"Gaubatz","year":"2020","journal-title":"Lipids"},{"key":"10.1016\/j.numecd.2025.104214_bib92","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jama.292.12.1440","article-title":"Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial","volume":"292","author":"Esposito","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2025.104214_bib93","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1080\/10408398.2021.1876625","article-title":"The effect of paleolithic diet on glucose metabolism and lipid profile among patients with metabolic disorders: a systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Sohouli","year":"2022","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.numecd.2025.104214_bib94","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"EsccfP","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2025.104214_bib95","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib96","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/HCO.0000000000000962","article-title":"N-3 polyunsaturated fatty acids for cardiovascular risk","volume":"37","author":"Goff","year":"2022","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib97","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/13543784.2016.1254187","article-title":"Lomitapide for the treatment of hypertriglyceridemia","volume":"25","author":"Brahm","year":"2016","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.numecd.2025.104214_bib98","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","article-title":"Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide","volume":"174","author":"Sacks","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.numecd.2025.104214_bib99","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12020-020-02506-y","article-title":"Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome","volume":"71","author":"Cefalu","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.numecd.2025.104214_bib100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2022.08.017","article-title":"Efficacy and safety of lomitapide in familial chylomicronaemia syndrome","volume":"359","author":"Cefalu","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2025.104214_bib101","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib102","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2025.104214_bib103","article-title":"The future of lipid-lowering therapy","volume":"8","author":"Zwol","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.numecd.2025.104214_bib104","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104214_bib105","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104214_bib106","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib107","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200325","article-title":"RNA interference therapy targeting apolipoprotein C-iii in hypertriglyceridemia","volume":"2","author":"Gaudet","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.numecd.2025.104214_bib108","doi-asserted-by":"crossref","first-page":"A10357","DOI":"10.1161\/circ.144.suppl_1.10357","article-title":"ARO-APOC3, an investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hypertriglyceridemia","volume":"144","author":"Clifton","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2025.104214_bib109","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib110","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2025.104214_bib111","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104214_bib112","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts","volume":"29","author":"Watts","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.numecd.2025.104214_bib113","doi-asserted-by":"crossref","DOI":"10.1161\/circ.148.suppl_1.17120","article-title":"ARO-ANG3, an investigational RNAi therapeutic, silences the expression of ANGPTL3 and decreases atherogenic lipoproteins in patients with mixed dyslipidemia: ARCHES-2 study results","volume":"148","author":"Watts","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2025.104214_bib114","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104214_bib115","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray","year":"2025","journal-title":"Lancet"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325003680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325003680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T01:02:14Z","timestamp":1763600534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475325003680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":115,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0939475325003680"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104214","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus document on the role of plasma triglycerides in cardiovascular disease from the Italian Society for the Study of Atherosclerosis (SISA)","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104214"}}